Zoloft and Haemangioma of skin - a phase IV clinical study of FDA data

Summary:

Haemangioma of skin is found among people who take Zoloft, especially for people who are female, 40-49 old.

The phase IV clinical study analyzes which people take Zoloft and have Haemangioma of skin. It is created by eHealthMe based on reports of 122,114 people who have side effects when taking Zoloft from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On May, 30, 2023

122,114 people reported to have side effects when taking Zoloft.
Among them, 20 people (0.02%) have Haemangioma of skin.

What is Zoloft?

Zoloft has active ingredients of sertraline hydrochloride. It is often used in depression. eHealthMe is studying from 132,457 Zoloft users for its effectiveness, alternative drugs and more.

What is Haemangioma of skin?

Haemangioma of skin (noncancerous, abnormally dense collections of dilated small blood vessels that may occur in the skin or internal organs) is found to be associated with 536 drugs and 280 conditions by eHealthMe.

Number of Zoloft and Haemangioma of skin reports submitted per year:

Gender of people who have Haemangioma of skin when taking Zoloft *:

female: 63.16 %
male: 36.84 %

Age of people who have Haemangioma of skin when taking Zoloft *:

Common drugs people take besides Zoloft *:

Common side effects people have besides Haemangioma of skin *:

Fever: 11 people, 55.00%
Otitis Media (inflammation of the middle ear): 11 people, 55.00%
Otitis (ear infection): 11 people, 55.00%
Diarrhea: 11 people, 55.00%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 11 people, 55.00%
Nausea And Vomiting: 11 people, 55.00%
Cellulitis (infection under the skin): 11 people, 55.00%
Hypoacusis (loss of hearing): 6 people, 30.00%
Fatigue (feeling of tiredness): 5 people, 25.00%
Memory Loss: 5 people, 25.00%

Common conditions people have *:

Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 4 people, 20.00%
Constipation: 4 people, 20.00%
Dehydration (dryness resulting from the removal of water): 2 people, 10.00%
Agitation (state of anxiety or nervous excitement): 2 people, 10.00%
Primary Myelofibrosis (primary disorder of the bone marrow): 1 person, 5.00%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 5.00%
Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs): 1 person, 5.00%
Ear Disorder: 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Zoloft and have Haemangioma of skin?

Check whether Haemangioma of skin is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Izgi C, Erdem G, Mansuroglu D, Kurtoglu N, Kara M, Gunesdogdu F, "Severe hypokalemia probably associated with sertraline use", Annals of Pharmacotherapy, 2014 Jan .

Related studies

How severe was Haemangioma of skin and when was it recovered:

Haemangioma of skin in Zoloft

Expand to all the drugs that have ingredients of sertraline hydrochloride:

Haemangioma of skin and drugs with ingredients of sertraline hydrochloride (15 reports)

Alternative drugs to, pros and cons of Zoloft:

Zoloft (132,457 reports)

Common Zoloft side effects:

Stress and anxiety: 9,019 reports
Depression: 8,834 reports
Fatigue (feeling of tiredness): 8,501 reports
Drug ineffective: 7,729 reports
Headache (pain in head): 7,422 reports
Pain: 7,095 reports
Weakness: 6,527 reports

Browse all side effects of Zoloft:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Haemangioma of skin treatments and more:

Haemangioma of skin (542 reports)

COVID vaccines that are related to Haemangioma of skin:

Common drugs associated with Haemangioma of skin:

Gilenya: 174 reports

How the study uses the data?

The study uses data from the FDA. It is based on sertraline hydrochloride (the active ingredients of Zoloft) and Zoloft (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.